GENNEX LABORATORIES
|
GENNEX LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.80 | 0.50 | 0.35 | 0.32 | 0.32 |
| CEPS(Rs) | 0.88 | 0.68 | 0.33 | 0.36 | 0.37 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 7.96 | 7.24 | 4.53 | 3.46 | 3.14 |
| Tax Rate(%) | 15.30 | 20.11 | 22.79 | 22.98 | 20.23 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 10.69 | 17.32 | 6.53 | 8.24 | 10.26 |
| EBIT Margin(%) | 16.00 | 19.90 | 10.75 | 9.15 | 9.12 |
| Pre Tax Margin(%) | 13.70 | 16.77 | 8.87 | 7.80 | 7.95 |
| PAT Margin (%) | 11.60 | 13.40 | 6.85 | 6.01 | 6.34 |
| Cash Profit Margin (%) | 12.87 | 15.81 | 8.13 | 7.22 | 7.73 |
| Performance Ratios | |||||
| ROA(%) | 7.46 | 7.28 | 4.92 | 6.18 | 6.97 |
| ROE(%) | 10.49 | 10.77 | 7.95 | 9.39 | 10.71 |
| ROCE(%) | 12.49 | 13.64 | 10.19 | 11.82 | 13.24 |
| Asset Turnover(x) | 0.64 | 0.54 | 0.72 | 1.03 | 1.10 |
| Sales/Fixed Asset(x) | 1.97 | 1.17 | 1.17 | 2.14 | 2.10 |
| Working Capital/Sales(x) | 1.14 | 0.81 | 3.75 | 2.84 | 3.67 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.51 | 0.86 | 0.85 | 0.47 | 0.48 |
| Receivable days | 37.35 | 50.53 | 52.65 | 53.05 | 39.96 |
| Inventory Days | 71.39 | 75.85 | 59.51 | 35.67 | 35.71 |
| Payable days | 53.27 | 83.15 | 67.75 | 65.55 | 71.92 |
| Valuation Parameters | |||||
| PER(x) | 15.12 | 31.60 | 16.00 | 22.14 | 11.69 |
| PCE(x) | 13.63 | 23.12 | 16.97 | 20.22 | 10.06 |
| Price/Book(x) | 1.51 | 2.18 | 1.24 | 2.17 | 1.25 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 1.76 | 3.66 | 1.55 | 1.59 | 0.93 |
| EV/Core EBITDA(x) | 8.94 | 14.47 | 11.72 | 14.36 | 7.90 |
| EV/EBIT(x) | 9.71 | 16.22 | 13.12 | 16.26 | 9.60 |
| EV/CE(x) | 1.15 | 1.68 | 1.04 | 1.43 | 0.95 |
| M Cap / Sales | 1.99 | 4.14 | 1.51 | 1.56 | 0.83 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 59.03 | 32.18 | 7.17 | 2.62 | 7.25 |
| Core EBITDA Growth(%) | 23.75 | 153.70 | 27.91 | -4.23 | 68.10 |
| EBIT Growth(%) | 27.79 | 153.25 | 29.41 | 2.85 | 75.81 |
| PAT Growth(%) | 37.55 | 167.74 | 25.43 | -2.85 | 117.53 |
| EPS Growth(%) | 59.35 | 42.59 | 8.05 | 1.67 | 117.59 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.13 | 0.12 | 0.22 | 0.23 | 0.19 |
| Current Ratio(x) | 4.07 | 4.01 | 1.65 | 1.95 | 1.91 |
| Quick Ratio(x) | 3.26 | 3.39 | 1.12 | 1.63 | 1.65 |
| Interest Cover(x) | 6.93 | 6.36 | 5.71 | 6.80 | 7.81 |
| Total Debt/Mcap(x) | 0.09 | 0.05 | 0.17 | 0.11 | 0.15 |
Compare Financial Ratios of peers of GENNEX LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GENNEX LABORATORIES | ₹259.4 Cr | 4.6% | 13.7% | -22% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹399,549.0 Cr | -1.9% | -7.3% | -2.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹166,862.0 Cr | 1.8% | 3.3% | 9.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹139,912.0 Cr | -0.5% | -4% | 29.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,891.0 Cr | 0.2% | -4.9% | 6.6% | Stock Analytics | |
| CIPLA | ₹99,591.5 Cr | 0.5% | -3.8% | -17% | Stock Analytics | |
GENNEX LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GENNEX LABORATORIES | 4.6% |
13.7% |
-22% |
| SENSEX | 3.2% |
5% |
5.5% |
You may also like the below Video Courses
